Compare Amgen, Inc. (AMGN) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Intuit Inc. — how do they compare? Amgen, Inc. trades at $417.12 (market cap $225.15B), while Intuit Inc. trades at $341.65 (market cap $91.56B). The key difference: Amgen, Inc. is far larger — about 2.5× Intuit Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | INTU | |
|---|---|---|
Market Cap | $225.15B | $91.56B |
Sector | Health | Technology |
52-Week High | $417.20 | $717.21 |
52-Week Low | $271.18 | $255.07 |
Enterprise Value | $268.47B | $90.01B |
Dividend Yield | 2.42% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Intuit (INTU) trades at $336.44, up 0.6% today, with a bullish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, with a net income margin of 21.91%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to pricing issues, contributing to a 20% stock drop recently noted by Forbes on June 2, 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $402.26 suggest upside, but legal risks and overbought RSI levels near 81.6 pose near-term challenges. Investors should weigh the company's AI-driven growth in financial software against regulatory scrutiny and competitive pressures in the fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
